Patents by Inventor HongYing Yun

HongYing Yun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10618929
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: April 14, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Dongdong Chen, Song Feng, Lu Gao, Chao Li, Baoxia Wang, Lisha Wang, Hongying Yun, Xiufang Zheng
  • Publication number: 20200109144
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: August 2, 2019
    Publication date: April 9, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Chungen Liang, Jianping Wang, Kun Miao, Hongying Yun, Xiufang Zheng
  • Patent number: 10590146
    Abstract: The present invention relates to compounds of formula (I), wherein R1 to R4 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: March 17, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Lisha Wang, Hongying Yun, Xiufang Zheng
  • Patent number: 10590112
    Abstract: This invention relates to new benzazepine carboxamide compounds of the formula wherein X and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR8 agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: March 17, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Fabian Dey, Lisha Wang, Hongying Yun, Weixing Zhang, Zhiwei Zhang, Wei Zhu
  • Patent number: 10544102
    Abstract: This invention relates to new benzazepine dicarboxamide compounds of the formula wherein R1 to R4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: January 28, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Lisha Wang, Hongying Yun, Weixing Zhang, Wei Zhu, Zhiwei Zhang
  • Patent number: 10428027
    Abstract: This invention relates to novel sulfinylphenyl or sulfonimidoylphenyl benzazepine compounds of the formula wherein X and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: October 1, 2019
    Assignee: Hoffmann La-Roche Inc.
    Inventors: Sabine Hoves, Lisha Wang, Hongying Yun, Weixing Zhang, Wei Zhu
  • Patent number: 10399983
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: September 3, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Chungen Liang, Jianping Wang, Kun Miao, Hongying Yun, Xiufang Zheng
  • Publication number: 20190256515
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: January 29, 2019
    Publication date: August 22, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lu Gao, Chungen Liang, Hongying Yun, Xiufang Zheng, Jianping Wang, Kun Miao, Bo Zhang
  • Patent number: 10370338
    Abstract: This invention relates to new benzazepine dicarboxamide compounds of the formula wherein R1 to R3 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: August 6, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Lisha Wang, Hongying Yun, Weixing Zhang, Wei Zhu, Zhiwei Zhang
  • Publication number: 20190169222
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: July 2, 2018
    Publication date: June 6, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Dongdong Chen, Song Feng, Lu Gao, Chao Li, Baoxia Wang, Lisha Wang, Hongying Yun, Xiufang Zheng
  • Publication number: 20190135788
    Abstract: This invention relates to new benzazepine carboxamide compounds of the formula wherein X and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR8 agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.
    Type: Application
    Filed: December 7, 2018
    Publication date: May 9, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Fabian Dey, Lisha Wang, Hongying Yun, Weixing Zhang, Zhiwei Zhang, Wei Zhu
  • Patent number: 10233184
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: March 19, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Lu Gao, Chungen Liang, Hongying Yun, Xiufang Zheng, Jianping Wang, Kun Miao, Bo Zhang
  • Publication number: 20190077763
    Abstract: This invention relates to new benzazepine dicarboxamide compounds of the formula wherein R1 to R3 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.
    Type: Application
    Filed: November 13, 2018
    Publication date: March 14, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lisha Wang, Hongying Yun, Weixing Zhang, Wei Zhu, Zhiwei Zhang
  • Publication number: 20190077764
    Abstract: This invention relates to new benzazepine dicarboxamide compounds of the formula wherein R1 to R4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.
    Type: Application
    Filed: November 13, 2018
    Publication date: March 14, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lisha Wang, Hongying Yun, Weixing Zhang, Wei Zhu, Zhiwei Zhang
  • Patent number: 10189838
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R6, W1, W2, W3, A and X are as described herein, compositions including the compounds and methods of using the compounds for the treatment and prophylaxis of respiratory syncytial virus infection.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: January 29, 2019
    Assignee: Hoffman-La Roche Inc.
    Inventors: Lisha Wang, Lu Gao, Mengwei Huang, Lei Guo, Chungen Liang, Wei Zhu, Song Feng, Xiufang Zheng, Weixing Zhang, Guolong Wu, Baoxia Wang, Hongying Yun
  • Patent number: 10183954
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: January 22, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Haixia Liu, Guolong Wu, Hongying Yun
  • Patent number: 10065973
    Abstract: The present invention relates to compounds of formula (I), wherein R1 to R5 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: September 4, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Baoxia Wang, Lisha Wang, Hongying Yun, Xiufang Zheng
  • Patent number: 10040815
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: August 7, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Dongdong Chen, Song Feng, Lu Gao, Chao Li, Baoxia Wang, Lisha Wang, Hongying Yun, Xiufang Zheng
  • Publication number: 20180194735
    Abstract: This invention relates to novel sulfinylphenyl or sulfonimidoylphenyl benzazepine compounds of the formula wherein X and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.
    Type: Application
    Filed: March 8, 2018
    Publication date: July 12, 2018
    Applicant: Hoffmann La-Roche Inc.
    Inventors: Sabine Hoves, Lisha Wang, Hongying Yun, Weixing Zhang, Wei Zhu
  • Patent number: 10000512
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: June 19, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Song Feng, Haixia Liu, Guolong Wu, Hongying Yun, Dongdong Chen, Chao Li